Chimerix (CMRX) Stock Price, News & Analysis

Company Overview

Chimerix, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel antiviral therapeutics and immune-modulating agents. The company leverages its proprietary lipid conjugate platform to enhance the delivery and potency of small-molecule drugs, with a primary focus on serious viral pathogens and inflammatory conditions. Through this technology, Chimerix aims to address unmet medical needs by improving safety profiles and reducing dosing frequency compared to conventional treatments.

Chimerix’s lead product, Tembexa (brincidofovir), received regulatory approval for the treatment of smallpox under the U.S. Food and Drug Administration’s Animal Rule, marking a significant milestone as a medical countermeasure for potential biothreats. The company’s pipeline also includes CMX521, an oral antiviral candidate targeting norovirus, and additional preclinical programs designed to combat respiratory viruses and emerging infectious diseases. In parallel, Chimerix is advancing DSTAT, an immunomodulatory agent being explored for its potential to reduce inflammation and improve outcomes in severe viral infections.

In pursuing global health solutions, Chimerix collaborates with government agencies, research institutions and biopharmaceutical partners across North America, Europe and Asia. These partnerships support clinical development, regulatory strategy and manufacturing scale-up, ensuring broad access to critical therapies. The company’s supply of Tembexa is incorporated into national strategic stockpiles, reflecting its role in public health preparedness and biodefense initiatives.

Founded in 2000 and headquartered in Durham, North Carolina, Chimerix has built a multidisciplinary team of virologists, chemists and clinical development experts. Dean Y. Li, M.D., serves as President and Chief Executive Officer, guiding the company’s scientific vision and growth strategy. Under his leadership, Chimerix continues to explore innovative drug delivery approaches and expand its pipeline to deliver safe and effective treatments to patients confronting life-threatening viral diseases and inflammatory conditions.

Key Stats

• Today's Range: $8.54 to $8.54
• 50-Day Range: $8.54 to $8.54
• 52-Week Range: $0.75 to $8.55
• Volume: N/A
• Average Volume: 2.79 million shs
• Market Capitalization: $801.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.53
• Consensus Rating: Hold

Chimerix Stock Analysis - MarketRank™

Chimerix scored higher than 12% of companies evaluated by MarketBeat, and ranked 877th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Chimerix has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Chimerix has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Chimerix are expected to grow in the coming year, from ($0.99) to ($0.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Chimerix is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chimerix is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Chimerix has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CMRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Chimerix does not currently pay a dividend.

Dividend Growth

Chimerix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -2.49

Short Interest

There is no current short interest data available for CMRX.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for CMRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Chimerix insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.10% of the stock of Chimerix is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

45.42% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CMRX Stock Analysis - Frequently Asked Questions

How have CMRX shares performed this year?

Chimerix's stock was trading at $3.48 at the start of the year. Since then, CMRX stock has increased by 145.4% and is now trading at $8.54.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) issued its earnings results on Friday, March, 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.31 million.

How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Chimerix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Chimerix investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD), Pfizer (PFE) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 3/21/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CMRX
• CIK: 1117480
• Web: www.chimerix.com
• Phone: (919) 806-1074
• Fax: 919-806-1146
• Employees: 90
• Year Founded: 2000

Price Target and Rating

• Average Price Target for Chimerix: $8.53
• High Price Target: $8.55
• Low Price Target: $8.50
• Potential Upside/Downside: -0.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$82.10 million
• Net Margins: N/A
• Pretax Margin: -52,574.85%
• Return on Equity: -50.78%
• Return on Assets: -44.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.33
• Quick Ratio: 6.33

Sales & Book Value

• Annual Sales: $212 thousand
• Price / Sales: 3,778.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.17 per share
• Price / Book: 3.94

Miscellaneous

• Outstanding Shares: 93,804,000
• Free Float: 78,154,000
• Market Cap: $801.09 million
• Optionable: Optionable
• Beta: -0.17